DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL). (June 2017) - Arribas, A.J.